Cyclacel Pharmaceuticals Announces Reverse Stock Split

The latest announcement is out from Cyclacel Pharmaceuticals ( (CYCC) ).

On May 7, 2025, Cyclacel Pharmaceuticals announced a one-for-sixteen reverse stock split, effective May 12, 2025, to meet Nasdaq Capital Market’s share bid price requirements. The reverse stock split, approved by the board and stockholders, will consolidate every sixteen shares into one, affecting all shareholders uniformly without altering their percentage interest. The company’s common stock will continue trading under the symbol ‘CYCC’ with a new CUSIP number.

Spark’s Take on CYCC Stock

According to Spark, TipRanks’ AI Analyst, CYCC is a Underperform.

Cyclacel Pharmaceuticals is currently under significant financial strain, marked by operational inefficiencies and a weak financial position, as reflected in its low financial performance score. While the technical indicators suggest a neutral trend, the valuation is unattractive due to its negative P/E ratio and lack of dividend yield. These factors collectively result in a low overall stock score.

To see Spark’s full report on CYCC stock, click here.

More about Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer medicines based on cell cycle, epigenetics, and mitosis biology. The company is advancing its epigenetic/anti-mitotic program with plogosertib, a PLK1 inhibitor, targeting both solid tumors and hematological malignancies. Cyclacel aims to build a diversified biopharmaceutical business with a pipeline of novel drug candidates for oncology and hematology indications.

Average Trading Volume: 2,564,141

Technical Sentiment Signal: Strong Sell

Current Market Cap: $134.9M

See more insights into CYCC stock on TipRanks’ Stock Analysis page.